Integrated CD20/BCMA CAR Architecture for B Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases, such as systemic lupus erythematosus, are inadequate, with therapies like rituximab and obexelimab failing to meet primary endpoints, and there is a need for more effective B cell depletion strategies.
Innovation Solution
Development of a bispecific chimeric antigen receptor (CAR) that targets both CD20 and BCMA, comprising specific variable regions with high sequence identity, which can be expressed in T cells or NK cells to achieve targeted B cell depletion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies like rituximab or obexelimab are used to deplete B cells, then B cell depletion is achieved, but treatment effectiveness is insufficient as they failed to meet primary endpoints in clinical trials
Solution Approach 1:
The patent combines two antigen targets (CD20 and BCMA) into a single bispecific CAR construct, allowing T cells to simultaneously recognize and eliminate B cells expressing either marker. This merging of targeting capabilities overcomes the limitations of monoclonal antibodies that target only one antigen, thereby improving both reliability and productivity of B cell depletion.
Solution Approach 2:
The bisspecific CAR T cells are designed to target multiple B cell markers (CD20 and BCMA), making them universally effective against diverse B cell populations including those that may downregulate one marker. This multi-functionality ensures more reliable and complete B cell depletion compared to single-target therapies.
2Object-affected harmful factors
If B cell depletion therapy is applied to treat autoimmune diseases, then pathogenic B cells are removed, but current therapies fail to achieve sufficient clinical outcomes
Solution Approach 1:
By combining targeting of both CD20 and BCMA in a single CAR construct, the therapy achieves more comprehensive elimination of pathogenic B cells including plasma cells that express BCMA. This dual-targeting approach reliably reduces harmful B cell activity better than single-target therapies.
Solution Approach 2:
The invention changes the parameter of antigen specificity from single-target to dual-target, enabling the T cells to recognize and eliminate a broader spectrum of pathogenic B cells. This parameter change improves clinical treatment success by addressing the limitations of previous single-antigen therapies.
3Reliability
If a bisspecific CAR targeting both CD20 and BCMA is developed, then targeted B cell depletion is enhanced, but CAR structure and manufacturing complexity increases
Solution Approach 1:
The patent merges two antigen-binding specificities into a single CAR polypeptide structure, where the extracellular domain contains both anti-CD20 and anti-BCMA binding regions. This consolidated design achieves enhanced B cell depletion effectiveness while managing structural complexity through integrated architecture rather than separate components.
Data Source
AI summary
The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.